MYO7A_HUMAN,K1923R,0.265,-,-,-
MYO7A_HUMAN,K1925A,0.602,Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered DNA binding (Pr = 0.19 | P = 0.03), ELME000313,-
MYO7A_HUMAN,D1926E,0.753,Altered Metal binding (Pr = 0.23 | P = 0.04); Altered DNA binding (Pr = 0.19 | P = 0.03), ELME000313,-
MYO7A_HUMAN,I1931V,0.262,-,-,-
MYO7A_HUMAN,T1933A,0.108,-,-,-
MYO7A_HUMAN,T1933G,0.419,-,-,-
MYO7A_HUMAN,T1933L,0.432,-,-,-
MYO7A_HUMAN,K1938P,0.677,Loss of Helix (Pr = 0.28 | P = 0.02), ELME000053|ELME000106|ELME000146|ELME000313,-
MYO7A_HUMAN,S1939L,0.574,, ELME000053|ELME000197|ELME000313|ELME000333,-
MYO7A_HUMAN,S1939T,0.300,-,-,-
MYO7A_HUMAN,F1943R,0.944,, ELME000053|ELME000106|ELME000146|ELME000197,-
MYO7A_HUMAN,L1945D,0.962,Altered Stability (Pr = 0.24 | P = 8.8e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), None,-
MYO7A_HUMAN,L1945S,0.937,Altered Stability (Pr = 0.34 | P = 4.2e-03), None,-
MYO7A_HUMAN,K1948E,0.822,Altered Transmembrane protein (Pr = 0.11 | P = 0.03), None,-
MYO7A_HUMAN,K1948Q,0.756,Altered Transmembrane protein (Pr = 0.10 | P = 0.05), None,-
MYO7A_HUMAN,K1952A,0.836,Altered Transmembrane protein (Pr = 0.17 | P = 0.01), ELME000064|ELME000065|ELME000106|ELME000173,-
MYO7A_HUMAN,E1958D,0.588,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.17 | P = 0.01), ELME000064|ELME000065|ELME000321|PS00006,-
MYO7A_HUMAN,K1980R,0.274,-,-,-
MYO7A_HUMAN,S1986L,0.604,Altered Ordered interface (Pr = 0.26 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Gain of Proteolytic cleavage at D1981 (Pr = 0.12 | P = 0.04), ELME000052|ELME000233|ELME000333|PS00008,-
MYO7A_HUMAN,R2061W,0.403,-,-,-
MYO7A_HUMAN,Q2119V,0.916,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q2119 (Pr = 0.05 | P = 0.03), ELME000173,-
MYO7A_HUMAN,I2128V,0.109,-,-,-
MYO7A_HUMAN,V2138L,0.475,-,-,-
MYO7A_HUMAN,I2141A,0.676,Altered Stability (Pr = 0.64 | P = 7.4e-04); Altered Transmembrane protein (Pr = 0.27 | P = 6.8e-04); Altered Metal binding (Pr = 0.24 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.05), ELME000333|PS00006|PS00008,-
MYO7A_HUMAN,D2142E,0.321,-,-,-
MYO7A_HUMAN,P2143S,0.339,-,-,-
MYO7A_HUMAN,T2145S,0.184,-,-,-
MYO7A_HUMAN,D2147R,0.539,Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.30 | P = 8.7e-03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.26 | P = 0.01), ELME000052|ELME000100|ELME000108|ELME000146|PS00005,-
MYO7A_HUMAN,T2150I,0.339,-,-,-
MYO7A_HUMAN,T2155A,0.654,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053,-
MYO7A_HUMAN,W2160L,0.885,Altered Ordered interface (Pr = 0.33 | P = 9.9e-03); Loss of Loop (Pr = 0.28 | P = 0.01); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 9.7e-04); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|PS00001,-
MYO7A_HUMAN,S2161E,0.840,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Loop (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.21 | P = 4.1e-03); Altered DNA binding (Pr = 0.14 | P = 0.05); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000064|ELME000070|ELME000085|PS00001|PS00006,-
MYO7A_HUMAN,G2163A,0.570,Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|ELME000085,-
MYO7A_HUMAN,H2168D,0.892,Altered Ordered interface (Pr = 0.31 | P = 0.01); Gain of Loop (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.17 | P = 9.4e-03); Altered DNA binding (Pr = 0.17 | P = 0.03), ELME000120|ELME000147|ELME000182|ELME000220|ELME000336|PS00006,-
MYO7A_HUMAN,H2168P,0.918,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000120|ELME000182|ELME000336,-
MYO7A_HUMAN,I2171P,0.844,Altered Ordered interface (Pr = 0.29 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03); Altered Stability (Pr = 0.19 | P = 0.01); Altered Metal binding (Pr = 0.17 | P = 0.04); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000136|ELME000159|ELME000336,-
MYO7A_HUMAN,G2172S,0.812,Altered Metal binding (Pr = 0.23 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000336,-
MYO7A_HUMAN,R2176P,0.880,Gain of Loop (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000062|ELME000149,-
MYO7A_HUMAN,K2179T,0.815,Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000062|ELME000149,-
MYO7A_HUMAN,Y2188W,0.688,, ELME000147|ELME000148|ELME000317,-
MYO7A_HUMAN,L2193G,0.873,Altered Stability (Pr = 0.55 | P = 1.3e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03), ELME000052|ELME000053|ELME000148|ELME000317|ELME000336,-
MYO7A_HUMAN,T2195H,0.793,Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000052|ELME000053|ELME000148|ELME000336,-
MYO7A_HUMAN,I2198T,0.853,Gain of Intrinsic disorder (Pr = 0.50 | P = 1.7e-03); Altered Disordered interface (Pr = 0.30 | P = 0.02); Altered Stability (Pr = 0.15 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000052|ELME000053|ELME000063|ELME000163|ELME000182|ELME000202|ELME000336,-
MYO7A_HUMAN,Q2200E,0.644,Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000063|ELME000163|ELME000182|ELME000202,-
MYO7A_HUMAN,Q2200F,0.877,Loss of Intrinsic disorder (Pr = 0.48 | P = 8.9e-03); Altered Disordered interface (Pr = 0.34 | P = 0.01); Gain of Allosteric site at Y2197 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000063|ELME000120|ELME000163|ELME000182|ELME000202|ELME000336,-
MYO7A_HUMAN,M2201P,0.886,Altered Disordered interface (Pr = 0.32 | P = 0.01); Loss of Helix (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.18 | P = 8.4e-03); Altered Stability (Pr = 0.14 | P = 0.02), ELME000063|ELME000202,-
MYO7A_HUMAN,A2204D,0.573,Gain of Intrinsic disorder (Pr = 0.42 | P = 5.6e-03); Altered Disordered interface (Pr = 0.29 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.05); Loss of Methylation at K2207 (Pr = 0.09 | P = 0.05), None,-
MYO7A_HUMAN,G2210N,0.233,-,-,-
MYO7A_HUMAN,S2211P,0.268,-,-,-
MYO7A_HUMAN,R2212Y,0.331,-,-,-
MYO7A_HUMAN,S2213G,0.086,-,-,-
MYO7A_HUMAN,G2214C,0.304,-,-,-
MYO7A_HUMAN,T165A,0.761,Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Methylation at K164 (Pr = 0.23 | P = 1.8e-03); Loss of Catalytic site at S160 (Pr = 0.15 | P = 0.02), PS00008|PS00017,-
MYO7A_HUMAN,D1266G,0.907,Loss of Loop (Pr = 0.29 | P = 0.01), ELME000220|ELME000321|ELME000336|PS00006,-
MYO7A_HUMAN,R212C,0.931,Altered Disordered interface (Pr = 0.52 | P = 6.9e-04); Altered DNA binding (Pr = 0.47 | P = 1.2e-04); Altered Metal binding (Pr = 0.39 | P = 2.3e-04); Loss of Relative solvent accessibility (Pr = 0.35 | P = 2.2e-03); Loss of Allosteric site at R212 (Pr = 0.34 | P = 1.7e-03); Gain of Catalytic site at S210 (Pr = 0.30 | P = 1.4e-03); Altered Ordered interface (Pr = 0.26 | P = 0.01); Loss of Methylation at K215 (Pr = 0.19 | P = 8.5e-03); Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Gain of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03), ELME000070|ELME000197|ELME000198|ELME000233|PS00001|PS00005,-
MYO7A_HUMAN,W2077R,0.874,Gain of Helix (Pr = 0.28 | P = 0.02); Gain of B-factor (Pr = 0.27 | P = 9.5e-03); Loss of Allosteric site at W2077 (Pr = 0.27 | P = 8.6e-03); Gain of Phosphorylation at S2073 (Pr = 0.23 | P = 0.05), ELME000008|ELME000065|ELME000102|PS00004,-
MYO7A_HUMAN,E1812Q,0.822,Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.22 | P = 0.02), ELME000002|ELME000251,-
MYO7A_HUMAN,H133D,0.930,Altered Metal binding (Pr = 0.59 | P = 4.9e-04); Loss of Allosteric site at H133 (Pr = 0.30 | P = 3.8e-03); Altered Ordered interface (Pr = 0.29 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered DNA binding (Pr = 0.19 | P = 0.03); Loss of Catalytic site at H133 (Pr = 0.10 | P = 0.04), ELME000058,-
MYO7A_HUMAN,L326Q,0.955,Altered Metal binding (Pr = 0.39 | P = 8.6e-03); Gain of Allosteric site at H327 (Pr = 0.27 | P = 5.7e-03); Gain of Catalytic site at H327 (Pr = 0.22 | P = 9.0e-03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000193,-
MYO7A_HUMAN,R1347S,0.949,Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03); Altered DNA binding (Pr = 0.17 | P = 0.04); Altered Stability (Pr = 0.11 | P = 0.04), ELME000102|ELME000137|ELME000146|ELME000155,-
MYO7A_HUMAN,H133P,0.958,Altered Metal binding (Pr = 0.94 | P = 6.3e-05); Loss of Allosteric site at H133 (Pr = 0.37 | P = 1.0e-03); Altered Ordered interface (Pr = 0.30 | P = 0.03); Loss of Helix (Pr = 0.29 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.03); Loss of Catalytic site at H133 (Pr = 0.10 | P = 0.04), ELME000058,-
MYO7A_HUMAN,D1689N,0.350,-,-,-
MYO7A_HUMAN,I1045T,0.749,Gain of Allosteric site at F1048 (Pr = 0.22 | P = 0.02), ELME000337|PS00005,-
MYO7A_HUMAN,V67M,0.666,, ELME000148,-
MYO7A_HUMAN,L566P,0.942,Altered Metal binding (Pr = 0.31 | P = 3.5e-03); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Allosteric site at K568 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Altered Coiled coil (Pr = 0.10 | P = 0.04); Loss of Catalytic site at E567 (Pr = 0.08 | P = 0.05), None,-
MYO7A_HUMAN,G2187D,0.740,Altered Transmembrane protein (Pr = 0.11 | P = 0.04); Gain of Sulfation at Y2188 (Pr = 0.02 | P = 0.04), ELME000147|ELME000148|ELME000220|PS00006,-
MYO7A_HUMAN,L1484F,0.759,Altered Ordered interface (Pr = 0.35 | P = 4.2e-03); Loss of Loop (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03), ELME000063|ELME000155,-
MYO7A_HUMAN,D1502G,0.884,Altered Transmembrane protein (Pr = 0.17 | P = 0.01), ELME000182,-
MYO7A_HUMAN,R1343S,0.906,Altered Transmembrane protein (Pr = 0.34 | P = 2.4e-05); Altered DNA binding (Pr = 0.19 | P = 0.02); Gain of Catalytic site at R1347 (Pr = 0.10 | P = 0.04), ELME000080|ELME000137|ELME000146|ELME000197|ELME000198,-
MYO7A_HUMAN,R241G,0.950,Loss of Allosteric site at R241 (Pr = 0.39 | P = 7.0e-04); Altered Ordered interface (Pr = 0.33 | P = 0.01); Altered Metal binding (Pr = 0.27 | P = 7.0e-03); Altered DNA binding (Pr = 0.23 | P = 0.01); Gain of Catalytic site at K239 (Pr = 0.09 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000085|ELME000336,-
MYO7A_HUMAN,L435H,0.948,Altered Stability (Pr = 0.57 | P = 1.1e-03); Altered Metal binding (Pr = 0.35 | P = 3.1e-03); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Strand (Pr = 0.26 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered Transmembrane protein (Pr = 0.24 | P = 1.6e-03); Gain of Allosteric site at D437 (Pr = 0.24 | P = 0.01); Gain of Catalytic site at D437 (Pr = 0.11 | P = 0.03), ELME000062|ELME000063|ELME000149|ELME000233|ELME000333|ELME000335,-
MYO7A_HUMAN,E450Q,0.855,Altered Metal binding (Pr = 0.24 | P = 0.03); Altered Coiled coil (Pr = 0.24 | P = 0.02), ELME000193,-
MYO7A_HUMAN,S211G,0.886,Altered Disordered interface (Pr = 0.32 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.32 | P = 4.9e-03); Altered DNA binding (Pr = 0.31 | P = 2.5e-03); Altered Ordered interface (Pr = 0.28 | P = 0.05); Altered Metal binding (Pr = 0.26 | P = 9.4e-03); Loss of Allosteric site at R212 (Pr = 0.26 | P = 0.01); Loss of Catalytic site at R206 (Pr = 0.21 | P = 0.01); Gain of Methylation at K215 (Pr = 0.19 | P = 6.3e-03); Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Loss of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03), ELME000070|ELME000085|ELME000197|ELME000198|PS00001|PS00005,-
MYO7A_HUMAN,E1248K,0.857,, ELME000064|PS00006,-
MYO7A_HUMAN,R1146Q,0.522,Loss of Helix (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.24 | P = 2.0e-03), ELME000052|ELME000062|ELME000064,-
MYO7A_HUMAN,C635R,0.972,Altered Metal binding (Pr = 0.46 | P = 4.7e-03); Gain of Catalytic site at C635 (Pr = 0.41 | P = 1.6e-04); Loss of Allosteric site at R634 (Pr = 0.24 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000012|ELME000102|ELME000108|ELME000146,-
MYO7A_HUMAN,G1159V,0.881,, ELME000313,-
MYO7A_HUMAN,A1340P,0.945,Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Gain of Pyrrolidone carboxylic acid at Q1336 (Pr = 0.08 | P = 0.02), None,-
MYO7A_HUMAN,R373C,0.850,Altered Ordered interface (Pr = 0.29 | P = 0.02), ELME000063|ELME000106|PS00005,-
MYO7A_HUMAN,R1883Q,0.764,Gain of Acetylation at K1884 (Pr = 0.28 | P = 5.6e-03); Loss of Allosteric site at R1883 (Pr = 0.26 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.05); Altered Coiled coil (Pr = 0.13 | P = 0.04), ELME000070|ELME000102|ELME000134|ELME000202|PS00001|PS00005,-
MYO7A_HUMAN,R1708S,0.397,-,-,-
MYO7A_HUMAN,K2118N,0.686,Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Loop (Pr = 0.29 | P = 9.7e-03); Loss of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q2119 (Pr = 0.07 | P = 0.02); Gain of N-linked glycosylation at K2118 (Pr = 0.04 | P = 0.02), ELME000070|PS00001,-
MYO7A_HUMAN,G671S,0.900,Altered Ordered interface (Pr = 0.33 | P = 7.5e-03); Gain of Allosteric site at R675 (Pr = 0.27 | P = 6.2e-03); Altered DNA binding (Pr = 0.22 | P = 0.02); Altered Metal binding (Pr = 0.11 | P = 0.04); Gain of Catalytic site at Y672 (Pr = 0.08 | P = 0.05), ELME000008|ELME000048|ELME000061|ELME000062|PS00004,-
MYO7A_HUMAN,Y560S,0.921,Altered Ordered interface (Pr = 0.36 | P = 2.1e-03); Gain of Relative solvent accessibility (Pr = 0.33 | P = 2.4e-03); Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Altered Metal binding (Pr = 0.12 | P = 0.03); Altered Coiled coil (Pr = 0.09 | P = 0.05); Loss of Sulfation at Y559 (Pr = 0.02 | P = 0.04), ELME000163|ELME000202|PS00008,-
MYO7A_HUMAN,R657W,0.936,Gain of Strand (Pr = 0.28 | P = 0.01); Loss of Allosteric site at R657 (Pr = 0.28 | P = 7.3e-03); Altered DNA binding (Pr = 0.25 | P = 8.3e-03); Loss of Catalytic site at R657 (Pr = 0.22 | P = 9.4e-03), ELME000062|ELME000106|ELME000313|ELME000336,-
MYO7A_HUMAN,H2014R,0.912,Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.03); Loss of Allosteric site at Y2015 (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of Catalytic site at Y2015 (Pr = 0.16 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 6.7e-03); Gain of Sulfation at Y2016 (Pr = 0.03 | P = 0.02), PS00007,-
MYO7A_HUMAN,G1600R,0.772,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of ADP-ribosylation at R1604 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.18 | P = 8.9e-03); Altered DNA binding (Pr = 0.15 | P = 0.05), ELME000061|ELME000220|ELME000271,-
MYO7A_HUMAN,T1496K,0.882,Altered Ordered interface (Pr = 0.33 | P = 7.0e-03); Altered Transmembrane protein (Pr = 0.26 | P = 8.8e-04); Loss of N-linked glycosylation at N1494 (Pr = 0.03 | P = 0.03), ELME000070|ELME000080|ELME000137|PS00001,-
MYO7A_HUMAN,K1384N,0.739,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), None,-
MYO7A_HUMAN,R83S,0.861,Altered Ordered interface (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000045|ELME000106|ELME000146|PS00008,-
MYO7A_HUMAN,T1841R,0.832,, ELME000106|ELME000146,-
MYO7A_HUMAN,I1157N,0.883,Altered Stability (Pr = 0.10 | P = 0.04), ELME000137|ELME000313,-
MYO7A_HUMAN,C652Y,0.935,Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Allosteric site at R657 (Pr = 0.25 | P = 0.01); Loss of Catalytic site at R657 (Pr = 0.20 | P = 0.01); Altered DNA binding (Pr = 0.18 | P = 0.03), ELME000106|ELME000163|ELME000182|ELME000313,-
MYO7A_HUMAN,Y235D,0.957,Altered DNA binding (Pr = 0.32 | P = 8.9e-04); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Helix (Pr = 0.28 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.03); Loss of Allosteric site at Y235 (Pr = 0.26 | P = 0.01); Altered Metal binding (Pr = 0.24 | P = 0.01); Loss of Acetylation at K231 (Pr = 0.19 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Gain of Catalytic site at K239 (Pr = 0.10 | P = 0.04), ELME000182,-
MYO7A_HUMAN,V1669I,0.311,-,-,-
MYO7A_HUMAN,R816H,0.209,-,-,-
MYO7A_HUMAN,P1724A,0.259,-,-,-
MYO7A_HUMAN,I1157V,0.181,-,-,-
MYO7A_HUMAN,R1602Q,0.531,Gain of Helix (Pr = 0.27 | P = 0.05); Altered Ordered interface (Pr = 0.24 | P = 0.03); Loss of ADP-ribosylation at R1604 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.20 | P = 5.1e-03); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000008|ELME000012|ELME000102|ELME000134|ELME000233|ELME000271|ELME000278|PS00004,-
